RxDoctor Payments Data

Taylor Alloway, MD

Hospitalist · Jonesboro, ARNPI 1841677242

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 12 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Pfizer at 30.1% of the total. Reporting peaked in 2019 at $138 and has fallen 87.2% since, to $18 in 2024.

$224in general payments, 2019–2025

Across 12 payments — averaging $18.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$68
  • Merck$58
  • AbbVie$30
  • AstraZeneca$29
  • Supernus Pharmaceuticals, Inc.$24
  • Novartis$15

What the payments were for

  • Food & beverage$224100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer5$68
Merck1$58
AbbVie(2 entities)2$30
AstraZeneca(2 entities)2$29
Supernus Pharmaceuticals, Inc.1$24
Novartis1$15

How this compares

$224 in reported general payments places this provider in the 65th percentile of 125 hospitalist providers in Arkansas.

See all hospitalist providers in Arkansas

Medicare billing

Part B allowed, 2024
$334,926
Medicare patients
482
Services billed
2,811

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban22$12,258
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav71$441
Diltiazem Hcl16$261
Cefdinir28$227
Prednisone88$198
Azithromycin43$157
Tamsulosin Hcl15$141
Furosemide50$132
Clindamycin Hcl12$108
Doxycycline Hyclate14$107
Levofloxacin43$107
Bumetanide13$103
Amiodarone Hcl13$80
ClopidogrelClopidogrel Bisulfate17$70
Metronidazole11$69

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$68$12,25822 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 125 hospitalist providers in Arkansas.

Other hospitalist in Jonesboro

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →